1. Home
  2. AXSM vs AB Comparison

AXSM vs AB Comparison

Compare AXSM & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AXSM
    SELLHOLDBUYas of 15 hours ago
  • AB
    SELLHOLDBUYas of 15 hours ago
  • Stock Information
  • Founded
  • AXSM 2012
  • AB 1987
  • Country
  • AXSM United States
  • AB United States
  • Employees
  • AXSM N/A
  • AB N/A
  • Industry
  • AXSM Biotechnology: Pharmaceutical Preparations
  • AB Investment Managers
  • Sector
  • AXSM Health Care
  • AB Finance
  • Exchange
  • AXSM Nasdaq
  • AB Nasdaq
  • Market Cap
  • AXSM 4.2B
  • AB 4.3B
  • IPO Year
  • AXSM 2015
  • AB 1988
  • Fundamental
  • Price
  • AXSM $102.27
  • AB $40.33
  • Analyst Decision
  • AXSM Strong Buy
  • AB Strong Buy
  • Analyst Count
  • AXSM 13
  • AB 5
  • Target Price
  • AXSM $130.69
  • AB $43.00
  • AVG Volume (30 Days)
  • AXSM 1.0M
  • AB 487.8K
  • Earning Date
  • AXSM 02-18-2025
  • AB 02-04-2025
  • Dividend Yield
  • AXSM N/A
  • AB 7.63%
  • EPS Growth
  • AXSM N/A
  • AB 57.32
  • EPS
  • AXSM N/A
  • AB 3.49
  • Revenue
  • AXSM $338,457,000.00
  • AB $134,096,000.00
  • Revenue This Year
  • AXSM $44.77
  • AB N/A
  • Revenue Next Year
  • AXSM $67.70
  • AB $6.95
  • P/E Ratio
  • AXSM N/A
  • AB $11.58
  • Revenue Growth
  • AXSM 51.47
  • AB N/A
  • 52 Week Low
  • AXSM $64.11
  • AB $30.57
  • 52 Week High
  • AXSM $105.00
  • AB $40.80
  • Technical
  • Relative Strength Index (RSI)
  • AXSM 65.12
  • AB 68.09
  • Support Level
  • AXSM $91.81
  • AB $35.13
  • Resistance Level
  • AXSM $95.36
  • AB $40.80
  • Average True Range (ATR)
  • AXSM 4.80
  • AB 1.03
  • MACD
  • AXSM 1.94
  • AB 0.39
  • Stochastic Oscillator
  • AXSM 98.00
  • AB 91.62

Stock Price Comparison Chart: AXSM vs AB

AXSM
AB
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober20250102030405060708090100110AXSM VS AB

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

About AB AllianceBernstein Holding L.P.

AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (41%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of October 2024, AB had $793 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (42%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use